NSTM — Novelstem International Share Price
0.000.00%
Last trade - 00:00- $3.37m
- $7.28m
- $0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 234.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -23608.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.42 | n/a | n/a | 0.01 | 0.01 | n/a | n/a | -54.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +69.38 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NovelStem International Corp. is a development-stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.
Directors
- Jan Loeb CHM (62)
- Tracy Clifford DRC (52)
- Eric Richman DRC (59)
- Mitchell Rubenstein DRC (60)
- David Seltzer DRC (54)
- Jerry Wolasky DRC
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 22nd, 1993
- Public Since
- November 12th, 1993
- No. of Shareholders
- 80
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 46,881,475
- Address
- 2255 Glades Rd, Ste 237 W, BOCA RATON, 33431
- Web
- https://www.novelstem.com/
- Phone
- +1 5619988000
- Contact
- William Jones
- Auditors
- Cherry Bekaert LLP
Upcoming Events for NSTM
Q3 2024 Novelstem International Corp Earnings Release
Similar to NSTM
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Novelstem International share price?
As of Today at 22:24 UTC, shares in Novelstem International are trading at $0.07. This share price information is delayed by 15 minutes.
How has the Novelstem International share price performed this year?
Shares in Novelstem International last closed at $0.07 and the price had moved by -69.03% over the past 365 days. In terms of relative price strength the Novelstem International share price has underperformed the S&P500 Index by -74.01% over the past year.
What are the analyst and broker recommendations for Novelstem International?
There is no consensus recommendation for this security.
What is the Novelstem International dividend yield?
Novelstem International does not currently pay a dividend.
Does Novelstem International pay a dividend?
Novelstem International does not currently pay a dividend.
When does Novelstem International next pay dividends?
Novelstem International does not currently pay a dividend.
How do I buy Novelstem International shares?
To buy shares in Novelstem International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Novelstem International?
As of the previous close price of $0.07, shares in Novelstem International had a market capitalisation of $3.51m.
Where are Novelstem International shares listed?
Here are the trading details for Novelstem International:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NSTM
What kind of share is Novelstem International?
Based on an overall assessment of its quality, value and momentum Novelstem International is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Novelstem International share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Novelstem International share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novelstem International. Over the past six months, its share price has underperformed the S&P500 Index by -15.22%.
As of the last closing price of $0.07, shares in Novelstem International were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Novelstem International PE Ratio?
The Novelstem International PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Novelstem International?
Novelstem International's management team is headed by:
- Jan Loeb - CHM
- Tracy Clifford - DRC
- Eric Richman - DRC
- Mitchell Rubenstein - DRC
- David Seltzer - DRC
- Jerry Wolasky - DRC